| Id: | acc2323 |
| Group: | 2sens |
| Protein: | Smad2 |
| Gene Symbol: | SMAD2 |
| Protein Id: | Q15796 |
| Protein Name: | SMAD2_HUMAN |
| PTM: | phosphorylation |
| Site: | Ser465 |
| Site Sequence: | MGSPSVRCSSMS--------- |
| Disease Category: | Cancer |
| Disease: | Breast Cancer |
| Disease Subtype: | |
| Disease Cellline: | MCF7 |
| Disease Info: | |
| Drug: | SSA |
| Drug Info: | - |
| Effect: | modulate |
| Effect Info: | SSA can specifically reduce the motility of breast tumor cells by directly blocking the phosphorylation of Smad2/3 without affecting the growth of tumor cells. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 26769851 |
| Sentence Index: | 26769851_4-5 |
| Sentence: | "In this study, we focus on the inhibitory activity of SSA on breast tumor cell motility, which has not been studied previously. Our results show that SSA treatment at non-cytotoxic concentrations can specifically reduce breast tumor cell motility without influencing tumor cell growth, and the mechanism of action involves the suppression of TGFbeta signaling by directly blocking Smad2/3 phosphorylation." |
Sequence & Structure:
MSSILPFTPPVVKRLLGWKKSAGGSGGAGGGEQNGQEEKWCEKAVKSLVKKLKKTGRLDELEKAITTQNCNTKCVTIPSTCSEIWGLSTPNTIDQWDTTGLYSFSEQTRSLDGRLQVSHRKGLPHVIYCRLWRWPDLHSHHELKAIENCEYAFNLKKDEVCVNPYHYQRVETPVLPPVLVPRHTEILTELPPLDDYTHSIPENTNFPAGIEPQSNYIPETPPPGYISEDGETSDQQLNQSMDTGSPAELSPTTLSPVNHSLDLQPVTYSEPAFWCSIAYYELNQRVGETFHASQPSLTVDGFTDPSNSERFCLGLLSNVNRNATVEMTRRHIGRGVRLYYIGGEVFAECLSDSAIFVQSPNCNQRYGWHPATVCKIPPGCNLKIFNNQEFAALLAQSVNQGFEAVYQLTRMCTIRMSFVKGWGAEYRRQTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| SMAD2-Ser118 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -1.1 | ||||
| HGSC | |||||
| ccRCC | 0.246 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | 0.854 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| SMAD2-Thr172 | |
|---|---|
| Cancer | Intensity |
| BRCA | 0.002 |
| COAD | -0.816 |
| HGSC | 1.954 |
| ccRCC | -0.467 |
| GBM | |
| HNSC | -0.115 |
| LUAD | -0.6 |
| LUSC | 0.334 |
| non_ccRCC | -1.011 |
| PDAC | -0.765 |
| UCEC | 1.485 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| S | 465 | U | Head and neck squamous cell carcinoma | Phosphorylation | 21281788 ; 35022323 |
| S | 465 | U | Marfan syndrome | Phosphorylation | 15731757 |
| S | 465 | U | Gastric cancer | Phosphorylation | 23934187 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
